Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Dec 2, 2025 · CIK: 2022416
Sentiment: neutral
Topics: regulatory-filing, financial-statements, company-update
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K on Dec 2, 2025, with financial docs.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 2, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated in the Cayman Islands, is based in Ramat Gan, Israel, and operates in the biological products sector. Its stock trades on NASDAQ under the ticker SLXN.
Why It Matters
This filing indicates Silexion Therapeutics Corp. is making a regulatory disclosure and submitting financial documents, which could contain important updates for investors.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no immediate indication of significant risk or opportunity.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- December 2, 2025 (date) — Date of report
- Ramat Gan, Israel (location) — Principal executive offices
- NASDAQ (company) — Exchange
- SLXN (ticker) — Stock ticker symbol
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was Silexion Therapeutics Corp. formerly known as?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences.
On what date was the name change from Biomotion Sciences to Silexion Therapeutics Corp. effective?
The date of the name change was May 6, 2024.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the stock ticker symbol for Silexion Therapeutics Corp.?
The stock ticker symbol for Silexion Therapeutics Corp. is SLXN.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-12-02 08:33:29
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2534079.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 12KB
- image0.jpg (GRAPHIC) — 15KB
- 0001178913-25-003981.txt ( ) — 256KB
- slxn-20251202.xsd (EX-101.SCH) — 5KB
- slxn-20251202_def.xml (EX-101.DEF) — 18KB
- slxn-20251202_lab.xml (EX-101.LAB) — 27KB
- slxn-20251202_pre.xml (EX-101.PRE) — 20KB
- zk2534079_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 2, 2025, Silexion Therapeutics Corp issued a press release entitled " Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer ". A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated December 2, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: December 2, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer